Skip to main content


Books/Book Chapters

(partial listing)

  • Boyaka, P.N., A. Duverger, E. Cormet-Boyaka, and J.-N. Tournier. 2008. Mucosal immunity against anthrax. In: Immunity against mucosal pathogens. Editor: M.Vajdy. Springer Science. Chapter 13, pp367-381.

Peer Reviewed Articles

(partial listing)

  • Duverger A., J-M Carre, J. Jee, S.H. Leppla, E. Cormet-Boyaka, W-J. Tang, D. Tome, and P.N. Boyaka. 2010. Contributions of Edema Factor and Protective Antigen to the Induction of Protective Immunity by Bacillus anthracis Edema Toxin as an Intranasal Adjuvant. Journal of Immunology (in press)
  • Cormet-Boyaka, E., J.S. Hong, B.K. Berdiev, J.A. Fortenberry, J. Rennolds, J.P. Clancy, D.J. Benos, P.N. Boyaka, and E.J. Sorscher. 2009. A truncated CFTR protein rescues endogenous Delta F598-CFTR and corrects chloride transport in mice. FASEB Journal. 23(11):3743-51.
  • Rennolds. J., P.N. Boyaka, S.L. Bellis, and E. Cormet-Boyaka, E. 2008. Low temperature induces the delivery of mature and immature CFTR to the plasma membrane. Biochemical and Biophysical Research Communications. 366:1025-9.
  • Fukuiwa. T., S. Sekine, R. Kobayashi, H. Suzuki, K. Kataoka, R.S. Gilbert, Y. Kurono, P.N. Boyaka, A.M. Krieg, J.R. McGhee, and K. Fujihashi. 2008. A combination of Flt3 ligand cDNA and CPG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine. 26:4849-59.
  • Fischer R, Debbabi H, Blais A, Dubarry M, Rautureau M, Boyaka PN, Tome D. 2007. Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int Immunopharmacol. 7(10):1387-93.
  • Fischer R, Tome D, McGhee JR, Boyaka PN. 2007. Th1 and Th2 cells are required for both eosinophil - and neutrophil-associated airway inflammatory responses in mice. Biochem biophys Res Commun. 357(1):44-9.
  • Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, Boyaka PN, Kim SH, Horimoto T, Kweon MN, Kang CY. 2007. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine. 25(28):5189-98.
  • Duverger A, Jackson RJ, van Ginkel FW, Fischer R, Tafaro A, Leppla SH, Fujihashi K, Kiyono H, McGhee JR, Boyaka PN. 2006. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol. 176(3):1776-83
  • Fischer R, McGhee JR, Vu HL, Atkinson TP, Jackson RJ, Tome D, Boyaka PN. 2005. Oral and nasal sensitization promote distinct immune responses and lung reactivity in a mouse model of peanut allergy. Am J Pathol. 167(6):1621-30.
  • Lifrani A, Dubarry M, Rautureau M, Aattouri N, Boyaka PN, Tome D. 2005. Peanut-lupine antibody cross-reactivity is not associated to cross-allergenicity in peanut-sensitized mouse strains. Int Immunopharmacol. 5(9):1427-35.
  • Singh UP, Singh S, Boyaka PN, McGhee JR, Lillard JW Jr. 2004. Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8Rbeta interactions. J Leukoc Biol. 76(6):1240-7.
  • Sfeir RM, Dubarry M, Boyaka PN, Rautureau M, Tome D. 2004. The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr.134(2):403-9.
  • Ben Nasser I, Boyaka PN, Fennira Ben Aissa F, Jeddi M, Tome D. 2003. The [173-196] fragment of ovalbumin suppresses ovalbumin-specific rat IgE responses. Int Immunopharmacol. 3(12):1569-79.
  • Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol. 170(11):5636-43.
  • Boyaka PN, Ohmura M, Fujihashi K, Koga T, Yamamoto M, Kweon MN, Takeda Y, Jackson RJ, Kiyono H, Yuki Y, McGhee JR. 2003. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J Immunol. 170(1):454-62.
  • Lillard JW Jr, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR. 2003. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood. 101(3):807-14.
  • Boyaka PN, Marinaro M, Jackson RJ, van Ginkel FW, Cormet-Boyaka E, Kirk KL, Kensil CR, McGhee JR. 2001. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J Immunol. 166(4):2283-90.
  • Boyaka PN, Wright PF, Marinaro M, Kiyono H, Johnson JE, Gonzales RA, Ikizler MR, Werkhaven JA, Jackson RJ, Fujihashi K, Di Fabio S, Staats HF, McGhee JR. 2000. Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils. Am J Pathol. 157(6):2023-35.
  • Lillard JW Jr, Boyaka PN, Hedrick JA, Zlotnik A, McGhee JR. 1999. Lymphotactin acts as an innate mucosal adjuvant. J Immunol. 162(4):1959-65.
  • Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. 1999. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci U S A. 96(2):651-6.
  • Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR 1999. IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol. 162(1):122-8.
  • Marinaro M, Boyaka PN, Jackson RJ, Finkelman FD, Kiyono H, Jirillo E, McGhee JR. 1999. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J Immunol. 162(1):114-21.